Early drug development requires adherence to Good Manufacturing Practices (GMP) guidelines when manufacturing investigational medicinal products (IMPs) for clinical studies conducted within Europe. Studies which are directly supported by GMP-compliant on-site manufacturing facilities add substantial value by significantly cutting costs and timelines through proven, efficiency-focused processes.
Marijuana Effect on Differentiating an Opioid from Placebo During the Discrimination Phase of a Human Abuse Potential Study
Subjects of human abuse potential (HAP) studies must be able to detect liking with the investigational drug. However, many subjects recruited for HAP…
Favorable Regulatory Procedures In The Netherlands Phase I-IIa
The EU Clinical Trials Directive (CTD) has been fully implemented in The Netherlands. Prior to beginning a clinical trial, an identical Clinical…
Salt Lake City Research Unit
Video highlighting Salt Lake City Resarch Unit, and its capabilities